


CONTACT INFORMATION: Elana Holzman Tel +972-3-926-7554, E-mail: [elana.holzman@teva.co.il](mailto:elana.holzman@teva.co.il) Kevin Mannix Tel (215) 591-8912, E-mail: [kevin.mannix@tevausa.com](mailto:kevin.mannix@tevausa.com)

## Company Overview

Teva Pharmaceutical Industries Ltd., is among the top 15 pharmaceutical companies in the world and the leader in generic pharmaceuticals, specializing in development, production and marketing of a wide range of generic, innovative and branded pharmaceuticals, biogenerics and active pharmaceutical ingredients. Teva currently operates in over 60 countries with some 35,000 employees worldwide. Its innovative R&D efforts focus on therapies for the central nervous system (with emphasis

on multiple sclerosis), autoimmune diseases and oncology. Teva differentiates itself by balancing its portfolio with generic, innovative and branded products, vertically integrating its pharmaceutical and API activities, combining local customer responsiveness with a "global edge", and by its global footprint. Teva's success lies in the leadership of its management, the skills and devotion of its people, the quality of its offerings and its focus on customers and patients.

## Net Sales (U.S. \$ in Millions)




## Market Data (As of July 26, 2010)

Stock Symbol	TEVA
Closing Price	\$50.15
52 Week Range	\$48.57 - \$64.95
Market Capitalization	\$44.8 billion
#12 in NASDAQ-100	


**NASDAQ-100**




## Net Income<sup>(1,2)</sup> (U.S. \$ in Millions)




## Stock Chart (As of July 26, 2010)



## Earning Per Share<sup>(1,2)</sup> (U.S. \$)



## R&D Expenses (net) (U.S. \$ in Millions)



(1) Reflects non-GAAP results. (2) Reflects retroactive adjustment following the adoption of APB14-1.

## Recent Events

**July 1, 2010** - Teva announced that it has commercially launched Venlafaxine HCl ER Capsules, the Company's generic version of Wyeth's antidepressant Effexor XR<sup>®</sup>. The brand product had annual sales of approximately \$2.75 billion in the U.S., based on IMS sales data. As the first company to file an ANDA containing a paragraph IV certification for this product, Teva has been awarded a 180-day period of marketing exclusivity.

**June 18, 2010** - Teva announced that it has closed a \$2.5 billion debt offering in three tranches. Teva expects to use the proceeds from this offering to pay a portion of the purchase price for the acquisition of Merckle-ratiopharm group, repay approximately \$800 million of existing debt and for general corporate purposes. As a result of the offering, Teva, in combination with committed loan facilities and cash on hand, has secured sufficient financing to finance the acquisition of ratiopharm.

**June 4, 2010** - Teva announced positive results from a study assessing a new lower-volume injection of Copaxone<sup>®</sup> containing the currently approved dose in half the injection volume. The SONG study ('Study of New Glatiramer Acetate Formulation') explored the safety and tolerability of a 20mg/0.5mL injection of Copaxone<sup>®</sup> versus the current formulation of 20 mg/1.0mL. These findings were presented at the 24th Annual meeting

of the Consortium of Multiple Sclerosis Centers (CMSC) in San Antonio, Texas.

**June 1, 2010** - Teva announced that it has commercially launched Gianvi (drospirenone and ethinyl estradiol) Tablets, the Company's generic version of Bayer's Yaz<sup>®</sup> Tablets. Total sales of Yaz<sup>®</sup> Tablets were approximately \$782 million in the U.S. As the first company to file an ANDA containing a paragraph IV certification for this product, Teva has been awarded a 180-day period of marketing exclusivity.


**May 25, 2010** - Teva announced the FDA's approval and commercial launch of its generic version of GlaxoSmithKline's antiviral product, Valtrex<sup>®</sup> (valacyclovir hydrochloride) Tablets 500 mg and 1 g. Total annual sales of the product, including brand and generic sales, were approximately \$2.1 billion in the U.S., based on IMS sales data.

**May 19, 2010** - Teva announced that its subsidiary, Teva Canada, received a Notice of Compliance from Health Canada to market its generic version of Pfizer's Lipitor<sup>®</sup> (atorvastatin) Tablets, a product indicated for lowering cholesterol. Shipment of this product will commence immediately. Lipitor (atorvastatin) Tablets had annual brand sales of approximately \$1.3 billion in Canada.

## Sales by Region


Q2/10: \$3.8 billion

North America	65%
Europe <sup>(1)</sup>	21%
Latin America <sup>(2)</sup>	5%
Israel	3%
CEE	4%
ROW	2%



(1) Includes EU member states, Switzerland & Norway  
(2) Includes Mexico

## COPAXONE<sup>®</sup> Global In-Market Sales (U.S. \$ in Millions)



## U.S. Generic Pipeline (As of July 16, 2010)

**206 ANDAs** -  
**Over \$107 billion** in total branded sales  
**134 Paragraph IV filings**  
**82 First-to-File**  
**Over \$48 billion** in total branded sales

## Proprietary Branded Pharmaceuticals - Pipeline

Marketed products	End Phase III 2010-2012	End Phase III 2013-2015
Copaxone <sup>®</sup> Multiple Sclerosis	Women's Health	Innovative
Azilect <sup>®</sup> Parkinson's	Biologics	Respiratory
QVAR <sup>®</sup> Inhaled Steroid	Laquinimod - Oral Multiple Sclerosis (Phase III)	TV-1101 (OGX-011) (Phase III) Prostate Cancer 1st line
ProAir <sup>®</sup> Inhaled short acting beta-mimetic	StemEx <sup>®</sup> - Hemato-oncological (Phase III)	TV-1101 (OGX-011) (Phase III) Prostate Cancer 2nd line
Easi-Breathe products Asthma & COPD	Debrase - Burns (Phase III)	TV-1101 (OGX-011) Lung Cancer (Phase III)
Seasonique <sup>®</sup> / LoSeasonique <sup>®</sup> Extended Regimen Contraception	BDP HFA Nasal - Respiratory (Phase III)	DiaPep-277 - Type 1 Diabetes (Phase III)
PlanB <sup>®</sup> One-Step Emergency Contraception	4 Respiratory projects (undisclosed)	Laquinimod - Crohn's disease (Phase II)
ParaGard <sup>®</sup> Intrauterine Contraception	DR-103 - Contraception (Phase III)	CT-011 - Hemato - Oncological (Phase II)
Enjuvia <sup>™</sup> Hormone Therapy	Oxybutynin Vaginal Ring - Overactive Bladder (Phase III)	CT-011 - Solid Tumor Oncology (Phase II)
TEV-TROPIN <sup>®</sup> Growth Hormone Deficiency	Progesterone Vaginal Ring - Infertility (Phase III)	Laquinimod - Lupus (Phase II)
TevaGrastim <sup>®</sup> /Neuroval Hematology	DR-102 Contraception (Phase III)	TV-1390 - Multiple Sclerosis (Phase I)
	Neugranin - Hematology (Phase III)	2 Respiratory projects (undisclosed)
		2 Biosimilars projects (undisclosed)

## Selected Generic Approvals in the U.S (April - June 2010)

Product		Approval/Launch Date	Branded Product		Indication
			Name	Market size (U.S. \$ in Millions)	
Tamsulosin <sup>(1)</sup>	Capsules	27/4/10	Flomax <sup>®</sup>	2,291	Treatment of benign prostatic hyperplasia
Rosuvastatin <sup>(3)</sup>	Tablets	12/5/10	Crestor <sup>®</sup>	3,255	Treatment of primary hyperlipidemia and mixed dyslipidemia, hypertriglyceridemia, and homozygous familial hypercholesterolemia
Cinacalcet HCl <sup>(3)</sup>	Tablets	13/5/10	Sensipar <sup>®</sup>	470	Treatment of secondary hyperparathyroidism in patients with chronic kidney disease on dialysis. Also, treatment of hypercalcemia in patients with parathyroid carcinoma
Valacyclovir HCl <sup>(1)</sup>	Tablets	24/5/10	Valtrex <sup>®</sup>	2,151	Antiviral for treatment of cold sores, genital herpes, and herpes zoster
Adapalene <sup>(1)</sup>	Gel	2/6/10	Differin <sup>®</sup>	87	Acne vulgaris
Venlafaxine <sup>(1)(2)</sup>	ER Capsules	28/6/10	Effexor XR <sup>®</sup>	2,753	Treatment of major depressive disorder

(1) Launched (2) Exclusivity (180 days) (3) Tentative approval